Semaglutide (Ozempic/Wegovy): Complete Guide to Dosing, Weight Loss, and Side Effects

Semaglutide is arguably the most transformative drug in recent medical history. Whether you know it as Ozempic, Wegovy, or simply the GLP-1 shot, this once-weekly injectable has reshaped the conversation around obesity, type 2 diabetes, and cardiovascular disease. In clinical trials, it produced weight loss previously only seen with bariatric surgery — without going under the knife.

This guide covers everything: how semaglutide works, the difference between Ozempic and Wegovy, the complete titration schedule, what the clinical data actually shows, and who is (and isn't) a good candidate.

What Is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist developed by Novo Nordisk. It shares 94% sequence homology with human glucagon-like peptide-1 (GLP-1), a hormone naturally released from the gut after eating. The drug was engineered with a fatty acid side chain that binds to albumin in the bloodstream, dramatically extending its half-life to approximately one week — enabling once-weekly dosing instead of multiple daily injections.

GLP-1 itself has a half-life of under two minutes in the body. Semaglutide's albumin-binding modification solves that problem entirely, making it clinically practical in a way that native GLP-1 never was.

Mechanism of Action: How Semaglutide Works

Semaglutide binds to and activates GLP-1 receptors throughout the body. These receptors are found in the pancreas, brain, gut, heart, and other tissues. The drug's effects operate through several distinct pathways simultaneously:

Appetite Regulation in the Brain

GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signals. Semaglutide activates neurons in these regions involved in food intake regulation, reducing appetite and increasing the sense of fullness after smaller meals. Research suggests it also reduces cravings for high-calorie foods by modulating the reward centers of the brain — a mechanism distinct from simple appetite suppression.

Delayed Gastric Emptying

Semaglutide slows the rate at which food leaves the stomach and enters the small intestine. This prolongs feelings of fullness after eating and moderates the post-meal blood sugar spike. Over time, this effect tends to attenuate somewhat, but it remains clinically meaningful throughout treatment.

Pancreatic Effects

In the pancreas, semaglutide stimulates insulin secretion in a glucose-dependent manner (meaning it only increases insulin when blood sugar is elevated, significantly reducing hypoglycemia risk) and suppresses glucagon release. This dual action is central to its blood sugar-lowering effect in type 2 diabetes.

Ozempic vs. Wegovy: What's the Difference?

Both Ozempic and Wegovy contain the same active molecule — semaglutide — but they are FDA-approved for different indications and come in different dose ranges.

The higher target dose of Wegovy (2.4 mg vs. 1–2 mg for Ozempic) is responsible for the greater weight loss seen in obesity trials compared to diabetes trials. If you are prescribed Ozempic for weight loss "off-label," you are unlikely to reach the 2.4 mg exposure that drove the dramatic STEP trial results.

There is also now a high-dose version of Wegovy (7.2 mg) approved in 2025 for patients who need additional efficacy.

Complete Dosing Schedule

Both Ozempic and Wegovy use a slow titration to minimize gastrointestinal side effects. The FDA-approved escalation for Wegovy (for weight management) is:

Wegovy (Weight Management) Titration

• Weeks 1–4: 0.25 mg subcutaneous once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance)

If a dose increase causes intolerable side effects, the current dose can be extended for an additional 4 weeks before escalating. The goal is to reach 2.4 mg, but tolerability always comes first.

Ozempic (Type 2 Diabetes) Titration

• Weeks 1–4: 0.25 mg once weekly (starter dose — not a therapeutic dose)
• Week 5+: 0.5 mg once weekly
• If additional control needed: Increase to 1 mg, then 2 mg

Injection Technique

Semaglutide is injected subcutaneously into the abdomen, thigh, or upper arm — all sites produce equivalent drug exposure. Rotate injection sites weekly to prevent lipohypertrophy. Injections can be given at any time of day, with or without food.

Wegovy pens come pre-loaded with a built-in hidden needle and require no priming. An opened Wegovy pen can be stored for 28 days at room temperature or in the refrigerator (not frozen). Unopened pens should be refrigerated.

Clinical Results: What the Data Shows

Semaglutide's efficacy is backed by one of the most comprehensive clinical trial programs in obesity medicine history — the STEP (Semaglutide Treatment Effect in People with Obesity) program.

The STEP Trials

Across the STEP 1–5 trials, once-weekly semaglutide 2.4 mg produced the following results at 68 weeks in adults without diabetes:

• Mean weight loss: 14.9%–17.4% of body weight
• ≥10% weight loss achieved: 69%–79% of semaglutide participants vs. 12%–27% on placebo
• ≥15% weight loss achieved: 51%–64% of semaglutide participants
• ≥20% weight loss achieved: ~30% of participants in some cohorts

For context, prior pharmacological treatments for obesity rarely achieved more than 5–8% average weight loss. Semaglutide at 2.4 mg nearly doubled the best previous results.

STEP 5: Long-Term Efficacy

The STEP 5 trial extended follow-up to 104 weeks (two years). Weight loss was sustained throughout, with improvements in waist circumference, blood pressure, and HbA1c maintained at the two-year mark — demonstrating that semaglutide's effects do not meaningfully fade over the treatment period.

SELECT Trial: Cardiovascular Benefits

The SELECT trial enrolled over 17,000 adults with obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) by 20% compared to placebo over a median follow-up of over 3 years. This landmark finding led to Wegovy's expanded FDA indication for cardiovascular risk reduction in 2024.

Weight Regain After Stopping

The STEP 1 extension study provides a sobering data point: when semaglutide is discontinued, most weight is regained. Participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year, though they remained about 5.6% below their original baseline. This confirms that semaglutide treats obesity as a chronic condition — it works while you take it, but obesity tends to return when the drug is stopped, just as blood pressure rises again when antihypertensives are discontinued.

Side Effects and Safety

Common Side Effects

The most frequent side effects are gastrointestinal and are almost always dose-dependent and transient:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

These effects typically peak during dose escalation and diminish significantly once at a stable dose. Starting at 0.25 mg and titrating slowly is the single most effective strategy for minimizing dropout due to GI side effects.

Serious Side Effects

• Pancreatitis: Cases of acute pancreatitis, including fatal hemorrhagic and necrotizing forms, have been reported. Discontinue immediately if pancreatitis is suspected.
• Gallbladder disease: Rapid weight loss increases the risk of gallstones and cholecystitis.
• Thyroid C-cell tumors: Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures. It is unknown whether this risk applies to humans, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Diabetic retinopathy complications: Rapid improvement in glycemic control has been associated with worsening of diabetic retinopathy in some patients with pre-existing disease.

Muscle Loss Consideration

A notable concern with rapid semaglutide-driven weight loss is that a significant portion of weight lost can be lean mass (muscle), not just fat. Studies suggest roughly 25–40% of total weight lost may be lean tissue. Resistance training and adequate protein intake (at minimum 1.2–1.6 g per kg of body weight) during treatment are strongly recommended to preserve muscle mass.

Who Is a Candidate for Semaglutide?

Wegovy Eligibility

FDA-approved for adults with:

• BMI ≥30 (obesity), OR
• BMI ≥27 (overweight) with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)

Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy (discontinue at least 2 months before planned pregnancy)
• Prior serious hypersensitivity reaction to semaglutide

Compounded Semaglutide: What You Need to Know

During the height of the Ozempic/Wegovy shortage (2022–2024), compounding pharmacies produced semaglutide to meet demand. The FDA declared the shortage resolved for Wegovy in early 2024 and issued guidance restricting compounded copies. However, compounded semaglutide remains available through 503A compounding pharmacies for patients with documented allergies or specific medical needs.

If considering compounded semaglutide, verify the pharmacy is licensed in your state and PCAB-accredited, ask for a Certificate of Analysis (COA) confirming purity, and work with a licensed provider. Avoid "research chemical" semaglutide sold without a prescription — the quality controls are absent and the legal and health risks are real.

The Bottom Line

Semaglutide represents a genuine paradigm shift in how medicine addresses obesity and metabolic disease. The clinical evidence is among the strongest ever assembled for a weight-loss drug, and the cardiovascular data from the SELECT trial elevates it beyond just an aesthetic tool to a legitimate primary prevention medication.

That said, it is a long-term commitment. Stopping semaglutide means weight typically returns. For candidates — those with BMI ≥30, or ≥27 with comorbidities — the risk-benefit calculus is compelling. The key is combining it with protein-adequate nutrition and resistance training to protect muscle mass, and viewing it as one component of a broader metabolic health strategy.

If you are considering semaglutide, talk to a provider experienced in metabolic health, not just one who can write a prescription. The drug does the heavy lifting, but the lifestyle scaffolding around it determines long-term outcomes.